Post by merryfl on Mar 14, 2009 16:10:32 GMT -5
=============
Announcing Clinical Trials for Inhaled Cyclosporin
Yesterday at 5:00pm Are you waiting for a lung transplant or recently had one? Please read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America’s leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
Prev | Next
